{"id":"optimized-bismuth-quadruple-therapy","safety":{"commonSideEffects":[{"rate":"15-30","effect":"Nausea"},{"rate":"10-25","effect":"Diarrhea"},{"rate":"10-20","effect":"Abdominal discomfort"},{"rate":"5-15","effect":"Metallic taste"},{"rate":"common","effect":"Black stool (bismuth-related)"},{"rate":"5-10","effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL1592101","moleculeType":"Small molecule","molecularWeight":"394.09"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This regimen typically consists of bismuth subsalicylate, a proton pump inhibitor or H2-receptor antagonist, and two antibiotics (commonly metronidazole and tetracycline or clarithromycin). Bismuth acts as a bactericidal agent and mucosal protectant, while the combination of antimicrobials targets H. pylori through different pathways, reducing resistance development. The optimization refers to refined dosing, timing, and component selection to improve eradication rates and tolerability.","oneSentence":"Bismuth quadruple therapy combines bismuth subsalicylate with three antimicrobial agents to eradicate Helicobacter pylori infection through multiple mechanisms of action.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:58:30.777Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Helicobacter pylori infection eradication"}]},"trialDetails":[{"nctId":"NCT07104318","phase":"PHASE3","title":"Personalized vs Standard of Care Treatment for Helicobacter Pylori Eradication Among Veterans","status":"NOT_YET_RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2026-04-01","conditions":"Helicobacter Pylori","enrollment":360},{"nctId":"NCT07146594","phase":"PHASE4","title":"Clinical Evaluation of a 14day Modified Bismuth Quadruple Therapy for the Eradication of Helicobacter Pylori in a High Clarithromycin and Metronidazole Resistance Area Regarding Patients With Peptic Ulcer and Non Ulcer Dyspepsia","status":"NOT_YET_RECRUITING","sponsor":"Athens Medical Center","startDate":"2025-08-20","conditions":"Helicobacter Pylori Gastritis, Helicobacter Eradication","enrollment":150},{"nctId":"NCT05664685","phase":"PHASE4","title":"Optimized Bismuth Quadruple Therapy vs Triple Standard Therapy for Helicobacter Pylori Eradication","status":"COMPLETED","sponsor":"Pontificia Universidad Catolica de Chile","startDate":"2022-10-17","conditions":"Helicobacter Pylori Infection","enrollment":127}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":45,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Rama Intervención"],"phase":"marketed","status":"active","brandName":"Optimized bismuth quadruple therapy","genericName":"Optimized bismuth quadruple therapy","companyName":"Pontificia Universidad Catolica de Chile","companyId":"pontificia-universidad-catolica-de-chile","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Optimized bismuth quadruple therapy is a treatment for Helicobacter pylori infection, which involves a combination of medications including bismuth. Bismuth, a small molecule, acts as a coagulation factor XII activator, according to its mechanism of action.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}